Paget's disease of bone: Emphasis on treatment with zoledronic acid

Expert Review of Endocrinology and Metabolism

Volumn 4, Issue 5, 2009, Pages 423-434

  Polyzos, Stergios A ^a   Anastasilakis, Athanasios D ^b   Terpos, Evangelos ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b 424 General Army Hospital   (Greece)

^c Department of Clinical Therapeutics ^*  (Greece)

Author keywords

Alkaline phosphatase; Bisphosphonate; Bone markers; Bone metabolism; Bone turnover; Paget's disease of bone; Pamidronate; Remission; Risedronate; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; CPG 42446; DEOXYPYRIDINOLINE; ETIDRONIC ACID; HYDROXYPROLINE; IBANDRONIC ACID; MEVALONIC ACID; NERIDRONIC ACID; NITROGEN; PAMIDRONIC ACID; PLACEBO; PROTEIN P62; PYRIDINOLINE; RISEDRONIC ACID; SCAFFOLD PROTEIN; SEQUESTOSOME 1; TILUDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

BINDING AFFINITY; BIOCHEMISTRY; BONE EROSION; BONE METABOLISM; BONE PAIN; BONE TURNOVER; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; ENVIRONMENTAL FACTOR; ESOPHAGEAL IRRITATION; ESOPHAGUS DISEASE; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; HYPOCALCEMIA; INJECTION SITE PAIN; JAW OSTEONECROSIS; LOW DRUG DOSE; MORBIDITY; MORTALITY; MYALGIA; NAUSEA; NEPHROTOXICITY; OSTEOLYSIS; PAGET BONE DISEASE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RIGOR; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; VOMITING;

EID: 70349317218     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.09.35     Document Type: Review

References (66)

1. Cundy T, Bolland M. Paget disease of bone. Trends Endocrinol. Metab. 19(7), 246-253 (2008). • Comprehensive contemporary review of Paget's disease of bone (PDB).
2. Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone. Lancet 372(9633), 155-163 (2008). • Comprehensive contemporary review of the pathogenesis of PDB.
3. Hocking LJ, Lucas GJ, Daroszewska A et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum. Mol. Genet. 11(22), 2735-2739 (2002). (Pubitemid 35214900)
4. Xu J, Wu HF, Ang ES et al. NF-κB modulators in osteolytic bone diseases. Cytokine Growth Factor Rev. 20(1), 7-17 (2009).
5. Martini G, Gennari L, Merlotti D et al. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone 40(2), 457-463 (2007). (Pubitemid 46054544)
6. Polyzos SA, Anastasilakis AD, Efstathiadou Z et al. The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin and RANKL in patients with Paget's disease of bone. Horm. Metab. Res. DOI: 10.1055/s-0029-1233491 (2009) (Epub ahead of print). • Provides evidence for the impact of zoledronic acid (ZOL) on DKK-1, osteoprotegerin and RANKL in PDB.
7. Alvarez L, Peris P, Guanabens N et al. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum. 48(3), 824-828 (2003). (Pubitemid 36302021)
8. Mossetti G, Rendina D, De FG et al. Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment. Bone 36(3), 549-554 (2005). (Pubitemid 40403853)
9. Naot D, Bava U, Matthews B et al. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget's disease of bone. J. Bone Miner. Res. 22(2), 298-309 (2007). (Pubitemid 46167800)
10. Marshall MJ, Evans SF, Sharp CA, Powell DE, McCarthy HS, Davie MW. Increased circulating Dickkopf-1 in Paget's disease of bone. Clin. Biochem. 42(10-11), 965-969 (2009).
11. Cooper C, Harvey NC, Dennison EM, van Staa TP. Update on the epidemiology of Paget's disease of bone. J. Bone Miner. Res. 21(Suppl. 2), 3-8 (2006). • Provides current evidence on the epidemiology of PDB.
12. Cundy T. Is the prevalence of Paget's disease of bone decreasing? J. Bone Miner. Res. 21 (Suppl. 2), 9-13 (2006).
13. Bolland MJ, Tong PC, Naot D et al. Delayed development of Paget's disease in offspring inheriting SQSTM1 mutations. J. Bone Miner. Res. 22(3), 411-415 (2007). (Pubitemid 46797124)
14. Walsh JP, Attewell R, Stuckey BG et al. Treatment of Paget's disease of bone: a survey of clinical practice in Australia. Bone 42(6), 1219-1225 (2008). • Provides some valuable practical issues for the treatment of PDB with bisphosphonates (BPs).
15. Wermers RA, Tiegs RD, Atkinson EJ, Achenbach SJ, Melton LJ 3rd. Morbidity and mortality associated with Paget's disease of bone: a population-based study. J. Bone Miner. Res. 23(6), 819-825 (2008).
16. Langston AL, Campbell MK, Fraser WD, Maclennan G, Selby P, Ralston SH. Clinical determinants of quality of life in Paget's disease of bone. Calcif. Tissue Int. 80(1), 1-9 (2007). • First published paper from the Paget's Disease: a Randomized Trial of Intensive Versus Symptomatic Management (PRISM) study. (Pubitemid 46095744)
17. Reid IR, Davidson JS, Wattie D et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 35(1), 224-230 (2004). (Pubitemid 38789168)
18. Shankar S, Hosking DJ. Biochemical assessment of Paget's disease of bone. J. Bone Miner. Res. 21(Suppl. 2), 22-27 (2006).
19. Devogelaer JP, Bergmann P, Body JJ et al. Management of patients with Paget's disease: a consensus document of the Belgian Bone Club. Osteoporos. Int. 19(8), 1109-1117 (2008). • Contemporary consensus providing evidence for the management of PDB.
20. Deftos LJ. Treatment of Paget's disease-taming the wild osteoclast. N. Engl. J. Med. 353(9), 872-875 (2005).
21. Siris ES, Lyles KW, Singer FR, Meunier PJ. Medical management of Paget's disease of bone: indications for treatment and review of current therapies. J. Bone Miner. Res. 21(Suppl.), 294-298 (2006).
22. Colina M, La CR, De LF, Trotta F. Paget's disease of bone: a review. Rheumatol. Int. 28(11), 1069-1075 (2008).
23. Widler L, Jaeggi KA, Glatt M et al. Highly potent geminal bisphosphonates: from pamidronate disodium (Aredia) to zoledronic acid (Zometa). J. Med. Chem. 45(17), 3721-3738 (2002). (Pubitemid 34863233)
24. Russell RG. Bisphosphonates: from bench to bedside. Ann. NY Acad. Sci. 1068(1), 367-401 (2006).
25. Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J. Dent. Res. 86(11), 1022-1033 (2007).
26. Altman RD, Johnston CC, Khairi MR, Wellman H, Serafini AN, Sankey RR. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N. Engl. J. Med. 289(26), 1379-1384 (1973).
27. Dunford JE, Thompson K, Coxon FP et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296(2), 235-242 (2001). • Evidence for the ranking of potency of BPs to inhibit farnesyl pyrophosphate synthase. (Pubitemid 32112446)
28. Nancollas GH, Tang R, Phipps RJ et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38(5), 617-627 (2006). • Provides evidence for the ranking of binding affinity of BPs for hydroxyapatite.
29. Reid IR, Miller P, Lyles K et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N. Engl. J. Med. 353(9), 898-908 (2005). •• Provides evidence for therapeutic efficacy and safety of ZOL compared with risedronate (RIS). (Pubitemid 41247929)
30. AACE Ad Hoc Task Force. American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines. Endocr. Pract. 10(4), 353-361 (2004).
31. Arden-Cordone M, Siris ES, Lyles KW et al. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. Calcif. Tissue Int. 60(5), 415-418 (1997). • First clinical study of ZOL in patients with PDB. (Pubitemid 27183891)
32. Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD. Measurement of urinary excretion of nonisomerized and b-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthritis Rheum. 41(2), 354-360 (1998). (Pubitemid 28087704)
33. Buckler H, Fraser W, Hosking D et al. Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study. Bone 24(Suppl. 5), 81-85 (1999). (Pubitemid 29202004)
34. Garnero P, Christgau S, Delmas PD. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone. Bone 28(5), 461-464 (2001). (Pubitemid 32409996)
35. Jarrett SJ, Conaghan PG, Sloan VS et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum. 54(5), 1410-1414 (2006).
36. Hosking D, Lyles K, Brown JP et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J. Bone Miner. Res. 22(1), 142-148 (2007). •• Provides evidence for long-term remission on ZOL compared with RIS. (Pubitemid 46032607)
37. Patel S, Stone MD, Coupland C, Hosking DJ. Determinants of remission of Paget's disease of bone. J. Bone Miner. Res. 8(12), 1467-1473 (1993). (Pubitemid 23342684)
38. Merlotti D, Gennari L, Martini G et al. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone. J. Bone Miner. Res. 22(10), 1510-1517 (2007). • Provides evidence for therapeutic efficacy and safety of ZOL compared with pamidronate. (Pubitemid 351229321)
39. Avramidis A, Polyzos SA, Moralidis E et al. Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone. J. Bone Miner. Metab. 26(6), 635-641 (2008). • First study evaluating the effect of ZOL on scintigraphic imaging in PDB.
40. Chung G, Keen RW. Zoledronate treatment in active Paget's disease. Ann. Rheum. Dis. 62(3), 275-276 (2003). (Pubitemid 36238101)
41. Tziomalos K, Florentin M, Krikis N, Perifanis V, Karagiannis A, Harsoulis F. Persistent effect of zoledronic acid in Paget's disease. Clin. Exp. Rheumatol. 25(3), 464-466 (2007). (Pubitemid 47091027)
42. Tucci JR. Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone. Endocr. Pract. 14(5), 607-610 (2008).
43. Morton A. Pagetic hydrocephalus treated with zoledronate. Ann. Rheum. Dis. 64(9), 1386 (2005).
44. Pane A. Paget disease manifesting with compressive sixth-nerve palsy that resolved with intravenous zoledronic acid therapy. Arch. Ophthalmol. 125(10), 1440-1441 (2007). (Pubitemid 47606624)
45. Oikonomou A, Birbilis T, Gymnopoulou E, Prassopoulos P. Paget disease of the spine manifested by thoracic and lumbar epidural lipomatosis: magnetic resonance imaging findings. Spine 32(25), 789-792 (2007). (Pubitemid 351339382)
46. Polyzos SA, Anastasilakis AD, Terpos E. Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid. Support. Care Cancer DOI: 10.1007/s00520-009-0704-0705 (2009) (Epub ahead of print).
47. Shane E, Goldring S, Christakos S et al. Osteonecrosis of the jaw: more research needed. J. Bone Miner. Res. 21(10), 1503-1505 (2006). (Pubitemid 44484594)
48. Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J. Clin. Oncol. 23(34), 8580-8587 (2005). (Pubitemid 46211499)
49. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 62(5), 527-534 (2004). • Comprehensive systematic review on osteonecrosis of the jaws after BPs in malignant and non-malignant bone diseases. (Pubitemid 38542516)
50. Gueiros LA, Lopes MA, Leao JC. Paget's disease and bisphosphonate- associated osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 66(6), 1319-(2008). • A case of osteonecrosis of the jaws in PDB after ZOL.
51. Farrugia MC, Summerlin DJ, Krowiak E et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 116(1), 115-120 (2006). (Pubitemid 44383974)
52. Hay KD, Bishop PA. Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications. N. Z. Dent. J. 102(1), 4-9 (2006).
53. Terpos E, Sezer O, Croucher PI et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann. Oncol. 20(8), 1303-1317 (2009).
54. Labinson P, Taxel P. Multiple fractures in a woman receiving 24 years of etidronate treatment for Paget's disease. Conn. Med. 71(5), 269-273 (2007).
55. Boyce BF, Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT. Mineralisation defects after pamidronate for Paget's disease. Lancet 343(8907), 1231-1232 (1994). (Pubitemid 24147582)
56. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N. Engl. J. Med. 349(17), 1676-1679 (2003).
57. Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356(18), 1809-1822 (2007).
58. Fromigue O, Body JJ. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J. Endocrinol. Invest 25(6), 539-546 (2002). (Pubitemid 34661843)
59. Reinholz GG, Getz B, Pederson L et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 60(21), 6001-6007 (2000). (Pubitemid 30839630)
60. Ebert R, Zeck S, Krug R et al. Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. Bone 44(5), 858-864 (2009). • Provides evidence for the potential dual action of ZOL on human mesenchymal stem cells.
61. Fujita K, Janz S. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol. Cancer 6, 71(2007).
62. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J. Clin. Invest. 116(5), 1202-1209 (2006).
63. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357(9), 905-916 (2007).
64. Tenta R, Pitulis N, Tiblalexi D et al. Mechanisms of the action of zoledronic acid on human MG-63 osteosarcoma cells. Horm. Metab. Res. 40(11), 737-745 (2008). (Pubitemid 352772688)
65. Dass CR, Choong PF. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol. Cancer Ther. 6(12), 3263-3270 (2007).
66. Labrinidis A, Hay S, Liapis V, Ponomarev V, Findlay DM, Evdokiou A. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin. Cancer Res. 15(10), 3451-3461 (2009).